Loading...
Loading...
Cantor Fitzgerald initiates its coverage on Humana
HUM with a Buy rating and a price target of $95.
Cantor Fitzgerald notes, "Although its commercial business is relatively weak, Humana's large Medicare book is growing rapidly because of baby boomers aging into Medicare and choosing managed care, and the company's long-term strategy of reinvesting in more cost effective products that preserve the benefits its members find most attractive. This strategy, leveraged by greater consumer engagement, has also fostered better medical management. This has proven a competitive advantage as the government has implemented a program to cut Medicare Advantage reimbursement by 15% over a period of years."
HUM closed at $79.32 on Tuesday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in